In the paired subset, the percentage of CSF stage-3 individuals increased across the classification criteria whereas in plasma, stage-3 appeared to be a more prominent biomarker phenotype of advanced disease groups (AD, A+T+ , tau-PET Braak V–VI, and MT+/NC+). This evidence concerns the gene MAPT and Alzheimer disease.